Lv41
570 积分 2025-04-02 加入
Predicting treatment-free remission after thrombopoietin receptor agonist therapy in immune thrombocytopenia: real-world outcomes from a Korean cohort
10分钟前
已完结
Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial
1个月前
已完结
Complement activation profile in adult primary immune thrombocytopenia
3个月前
已关闭
A single-cell atlas of bone marrow B cells reveals defective central B-cell tolerance in immune thrombocytopenia
3个月前
已完结
Diagnosis and management of Evans syndrome in adults: first consensus recommendations
3个月前
已完结
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
1年前
已关闭
EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16
1年前
已完结
皖公网安备34019202002308
